Conoa-B (02162) rose more than 7% in the afternoon. As of press release, it was up 6.74% to HK$29.3, with a turnover of HK$404.85,500.
The Zhitong Finance App learned that Conoa-B (02162) rose more than 7% in the afternoon. As of press release, it had risen 6.74% to HK$29.3, with a turnover of HK$404.885,500.
According to the news, Conoa-B announced that its non-wholly-owned subsidiary KYM, with the biopharmaceutical company AstraZeneca (AZN.US), signed an exclusive global license agreement in February to develop and commercialize the company's pipeline product CMG901 (AZD0901). Up to now, AstraZeneca has conducted multiple clinical studies on CMG901 (AZD0901) for the treatment of advanced solid tumors.
Among them, an international multicenter phase III study comparing AZD0901 single drug and the plan selected by the researchers as second-line or higher-line treatment in subjects with advanced or metastatic gastric and gastroesophageal adenocarcinoma expressing Claudin 18.2 was announced on the drug clinical trial registration and information platform in March, and the first test subjects completed their first dose on April 11.